2. Academic Validation
  3. A Recombinant Targeted Bionanoparticle In Vitro Expressing a Gene-Editing Protein for Epidermal Growth Factor Receptor Mutant Lung Cancer

A Recombinant Targeted Bionanoparticle In Vitro Expressing a Gene-Editing Protein for Epidermal Growth Factor Receptor Mutant Lung Cancer

  • ACS Nano. 2026 Feb 17;20(6):4920-4941. doi: 10.1021/acsnano.5c17709.
Yuxin Ren 1 2,  Jiarui Xu 1 2,  Qian Luo 1 2,  Peishan Li 1 2,  Min Jiang 1 2,  Yuntao Cheng 1 2,  Hongrui Zhang 1 2,  Dingyi Wei 1 2,  Wenjing Bai 1 2,  Sunan Liu 1 2,  Guiling Wang 1 2,  Ying Xie 1 2,  Jianwei Li 1 2,  Wanliang Lu 1 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • 2 PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
PMID: 41645678 DOI: 10.1021/acsnano.5c17709
Abstract

Epidermal growth factor receptor (EGFR) mutation is a significant driving factor in the occurrence and progression of lung Cancer. How to effectively block the abnormal expression of EGFR remains a key issue that urgently needs to be addressed, as it is of vital importance for the effective treatment of this Cancer. Here, we report a recombinant targeted bionanoparticle that in vitro expresses Cas9 protein (tBioNP vitro-Cas9) for gene editing of EGFR mutant lung Cancer. The nanoparticle was developed by transfection of four plasmids (Gag-Cas9, Gag, sgRNA, VSV-G Azi) into 293T cells to form a type of bionanoparticle and modifying it with a targeted polymer material (DBCO-PEG-FA), and it showed a cancer-targeted property, faster Cancer cellular uptake, higher gene editing efficiency with lower off-target effects, and therapy efficacy in mice, indicating a translational prospect. In conclusion, the study provides a recombinant bionanoparticle in vitro expressing a Cas9 gene editing system and offers a potential strategy for gene therapy of EGFR mutant lung Cancer.

Keywords

EGFR; gene editing; in vitro expressing Cas9; lung cancer; recombinant bionanoparticle.

Figures
Products